AstraZeneca leans into GLP-1; Cuts looming at Bayer; Eli Lilly’s obesity approval; Endpoints Slack interview with Matt Gline; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Both Bayer and AstraZeneca took to their Q3 updates to unveil some big moves, albeit in somewhat different directions, while our team also highlighted the most interesting nuggets out of other companies’ earnings calls. Don’t miss our Slack interview with Roivant’s Matt Gline and look into early data on in vivo cell therapy, too.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.